The Appraisal Committee has prepared a Final Appraisal Document (FAD) on Entrectinib for treating ROS1 fusion-positive locally advanced or metastatic non-small-cell lung cancer [ID1541] and submitted it to NICE.
Entrectinib does not currently have a marketing authorisation in the UK for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors. Entrectinib will be made available on the NHS only if and when it receives its marketing authorisation for this indication. The anticipated marketing authorisation is expected in August 2020.
The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FAD has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5pm, Monday 29 June 2020.
This page was last updated: